01351nas a2200325   4500000000100000008004100001260001300042653001000055653002000065653002200085653001600107653001200123653003000135653001100165653001100176653002300187653001200210653001300222100001300235700001500248700001300263700001600276700001700292700001900309245008600328300001100414490000700425520057900432022001401011       2009                            d  c2009 Apr10aAdult10aAgranulocytosis10aAnemia, Hemolytic10aClofazimine10aDapsone10aDrug Therapy, Combination10aFemale10aHumans10aLeprostatic Agents10aleprosy10aRifampin1 aSilva IM1 aOliveira C1 aGuedes W1 aOliveira BB1 aOliveira DAP1 aGuedes Filho G00aAgranulocytosis induced by multidrug therapy in leprosy treatment: a case report.  a158-600 v133 a<p>Multidrug therapy (WHO/MDT) in multibacillary leprosy consists of treatment with rifampicin, dapsone and clofazimine. However, adverse effects can cause the patient to abandon treatment. We report on a patient who presented agranulocytosis and hemolytic anemia associated with this treatment regime. We also examined the importance of laboratory exams for diagnosis and follow-up of the patient, and for early detection of adverse effects,with a view to improving adhesion to treatment and contributing to the eradication of Hansen's disease as a public health issue.</p>  a1678-4391